International Journal of Antimicrobial Agents
Издатель: Elsevier · ISSN 0924-8579 · 80 статей
- Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort
- Daptomycin or linezolid versus vancomycin for the treatment of vancomycin-susceptible Enterococcus faecium bloodstream infections
- Silent carriage of tigecycline- and carbapenem-resistant Klebsiella quasipneumoniae co-harbouring tet(X4) and blaNDM-1 in healthy individuals in China
- Caspofungin pharmacokinetics in a child undergoing continuous veno-venous haemodiafiltration: A case report
- OmpK36 alterations are associated with reduced imipenem/relebactam susceptibility in KPC-2–producing Klebsiella pneumoniae, with dose-dependent restoration at higher relebactam concentrations
- Association between β-lactam concentration and liver injury in critically ill patients
- Efficacy and safety of P-CABs-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world evidence study
- Association of therapeutic antimicrobial class with incidence of acute complications and recurrent infection following non-severe streptococcal pharyngitis or tonsillitis
- Comment on “stepwise within-host evolution of a blaCTX-M-27-positive Klebsiella pneumoniae clone under changing antimicrobial pressures leading to enhancement of β-lactam resistance”
- blaNDM-4-carrying Klebsiella pneumoniae: an uncommon but epidemiologically informative signal in public genomes
- Comment on “Aztreonam– avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report”
- Comment on “The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against clostridioides difficile”
- In reply to the letter to editor regarding ‘discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms’
- In Reply to the Letter to Editor Regarding Tissue Pharmacokinetics of Antifungal Drugs: A Review
- In reply to letter to editor regarding ``a multicenter, randomised, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults''
- In reply to the Letter to the Editor regarding “Disrupting bacterial metabolism by targeting LDH reverses aminoglycoside resistance in Streptococcus suis”
- Comment on “Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first- and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms”
- Response to the Comment on ‘Burden and global distribution of antimicrobial resistance in nonbloodstream infections among adults with cirrhosis: A systematic review and proportional meta-analysis’
- Comment on “Isavuconazole prophylaxis and treatment in paediatric HSCT recipients: Pharmacokinetics, safety, and efficacy”
- In reply to the letter to the editor regarding ‘Stepwise within-host evolution of a blaCTX-M-27-positive Klebsiella pneumoniae clone under changing antimicrobial pressures leading to enhancement of β-lactam resistance’